New human data hints at psychedelics' potential to combat inflammation

Researchers are publishing some of the first human data suggesting psychedelics like psilocybin may lower inflammation and hold potential for patients with neurodegenerative diseases such as Parkinson's. Lab studies have shown protective effects, and these new findings in humans signal promise for treating inflammation-related conditions, though further research is needed.